Cellectis (NASDAQ:CLLS) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS) in a report issued on Saturday. The firm set a “sell” rating on the biotechnology company’s stock.

Cellectis Stock Performance

NASDAQ CLLS opened at $2.51 on Friday. The company has a market cap of $139.26 million, a P/E ratio of -1.50 and a beta of 3.12. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.20 and a quick ratio of 2.20. The stock has a 50-day moving average of $2.62 and a two-hundred day moving average of $2.63. Cellectis has a 1-year low of $0.96 and a 1-year high of $3.77.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.